Diagnosis and Treatment of Common Forms of Tremor

ABSTRACT

Tremor is the most common movement disorder presenting to an outpatient neurology practice and is defined as a rhythmical, involuntary oscillatory movement of a body part. The authors review the clinical examination, classification, and diagnosis of tremor. The pathophysiology of the more common forms of tremor is outlined, and treatment options are discussed. Essential tremor is characterized primarily by postural and action tremors, may be a neurodegenerative disorder with pathologic changes in the cerebellum, and can be treated with a wide range of pharmacologic and nonpharmacologic methods. Tremor at rest is typical for Parkinson's disease, but may arise independently of a dopaminergic deficit. Enhanced physiologic tremor, intention tremor, and dystonic tremor are discussed. Further differential diagnoses described in this review include drug- or toxin-induced tremor, neuropathic tremor, psychogenic tremor, orthostatic tremor, palatal tremor, tremor in Wilson's disease, and tremor secondary to cerebral lesions, such as Holmes' tremor (midbrain tremor). An individualized approach to treatment of tremor patients is important, taking into account the degree of disability, including social embarrassment, which the tremor causes in the patient's life.

KEYWORDS

Tremor - essential tremor - Parkinson's disease - dystonia - pathophysiology

REFERENCES

• 1 Deuschl G, Bain P, Brin M. Ad Hoc Scientific Committee . Consensus statement of the Movement Disorder Society on Tremor.  Mov Disord. 1998;  13 (Suppl 3) 2-23
• 2 Zesiewicz T A, Hauser R A. Phenomenology and treatment of tremor disorders.  Neurol Clin. 2001;  19 (3) 651-680, vii vii
• 3 Thanvi B, Lo N, Robinson T. Essential tremor-the most common movement disorder in older people.  Age Ageing. 2006;  35 (4) 344-349
• 4 Louis E D. Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry.  Lancet Neurol. 2010;  9 (6) 613-622
• 5 Louis E D, Rios E. Embarrassment in essential tremor: prevalence, clinical correlates and therapeutic implications.  Parkinsonism Relat Disord. 2009;  15 (7) 535-538
• 6 Elble R. The pathophysiology of tremor. In: Watts R L, Koller W C, eds. Movement Disorders: Neurologic Principles and Practice. 2nd ed. New York: McGraw Hill; 2004: 481-492
• 7 Van Der Giessen R S, Koekkoek S K, van Dorp S et al.. Role of olivary electrical coupling in cerebellar motor learning.  Neuron. 2008;  58 (4) 599-612
• 8 Llinás R, Yarom Y. Oscillatory properties of guinea-pig inferior olivary neurones and their pharmacological modulation: an in vitro study.  J Physiol. 1986;  376 163-182
• 9 Monsef H R, Ghobadi A, Iranshahi M, Abdollahi M. Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test.  J Pharm Pharm Sci. 2004;  7 (1) 65-69
• 10 Frison G, Favretto D, Zancanaro F, Fazzin G, Ferrara S D. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract.  Forensic Sci Int. 2008;  179 (2-3) e37-e43
• 11 Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats.  Parkinsonism Relat Disord. 2008;  14 (1) 33-36
• 12 Wilms H, Sievers J, Deuschl G. Animal models of tremor.  Mov Disord. 1999;  14 (4) 557-571
• 13 Goyal M, Versnick E, Tuite P et al.. Hypertrophic olivary degeneration: metaanalysis of the temporal evolution of MR findings.  AJNR Am J Neuroradiol. 2000;  21 (6) 1073-1077
• 14 Samuel M, Torun N, Tuite P J, Sharpe J A, Lang A E. Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors.  Brain. 2004;  127 (Pt 6) 1252-1268
• 15 Hess C W, Saunders-Pullman R. Movement disorders and alcohol misuse.  Addict Biol. 2006;  11 (2) 117-125
• 16 Pfeiffer R F. Wilson's disease.  Semin Neurol. 2007;  27 (2) 123-132
• 17 Ghika J, Vingerhoets F, Maeder P, Borruat F-X, Bogousslavsky J et al. EMC-Neurologie. 2004;  1 481-511
• 18 Mak C M, Lam C W. Diagnosis of Wilson's disease: a comprehensive review.  Crit Rev Clin Lab Sci. 2008;  45 (3) 263-290
• 19 Meshack R P, Norman K E. A randomized controlled trial of the effects of weights on amplitude and frequency of postural hand tremor in people with Parkinson's disease.  Clin Rehabil. 2002;  16 (5) 481-492
• 20 McGruder J, Cors D, Tiernan A M, Tomlin G. Weighted wrist cuffs for tremor reduction during eating in adults with static brain lesions.  Am J Occup Ther. 2003;  57 (5) 507-516
• 21 Lundervold D A, Poppen R. Biobehavioral intervention for older adults coping with essential tremor.  Appl Psychophysiol Biofeedback. 2004;  29 (1) 63-73
• 22 Shulman L M, Wen X, Weiner W J et al.. Acupuncture therapy for the symptoms of Parkinson's disease.  Mov Disord. 2002;  17 (4) 799-802
• 23 King L K, Almeida Q J, Ahonen H. Short-term effects of vibration therapy on motor impairments in Parkinson's disease.  NeuroRehabilitation. 2009;  25 (4) 297-306
• 24 Louis E D, Ottman R, Ford B et al.. The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research.  Neuroepidemiology. 1997;  16 (3) 124-133
• 25 Jankovic J, Beach J, Pandolfo M, Patel P I. Familial essential tremor in 4 kindreds. Prospects for genetic mapping.  Arch Neurol. 1997;  54 (3) 289-294
• 26 Whaley N R, Putzke J D, Baba Y, Wszolek Z K, Uitti R J. Essential tremor: phenotypic expression in a clinical cohort.  Parkinsonism Relat Disord. 2007;  13 (6) 333-339
• 27 Deuschl G, Elble R. Essential tremor—neurodegenerative or nondegenerative disease towards a working definition of ET.  Mov Disord. 2009;  24 (14) 2033-2041
• 28 Benito-León J, Louis E D. Essential tremor: emerging views of a common disorder.  Nat Clin Pract Neurol. 2006;  2 (12) 666-678, quiz 2p, 691
• 29 Putzke J D, Whaley N R, Baba Y, Wszolek Z K, Uitti R J. Essential tremor: predictors of disease progression in a clinical cohort.  J Neurol Neurosurg Psychiatry. 2006;  77 (11) 1235-1237
• 30 Singer C, Sanchez-Ramos J, Weiner W J. Gait abnormality in essential tremor.  Mov Disord. 1994;  9 (2) 193-196
• 31 Deuschl G, Wenzelburger R, Löffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction clinical and kinematic analysis of intention tremor.  Brain. 2000;  123 (Pt 8) 1568-1580
• 32 Lastres-Becker I, Rüb U, Auburger G. Spinocerebellar ataxia 2 (SCA2).  Cerebellum. 2008;  7 (2) 115-124
• 33 Spanaki C, Plaitakis A. Essential tremor in Parkinson's disease kindreds from a population of similar genetic background.  Mov Disord. 2009;  24 (11) 1662-1668
• 34 Vilariño-Güell C, Ross O A, Wider C et al.. LINGO1 rs9652490 is associated with essential tremor and Parkinson's disease.  Parkinsonism Relat Disord. 2010;  16 (2) 109-111
• 35 Vilarino-Guell C, Wider C, Ross O A et al.. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson's disease.  Neurogenetics. 11 (4) 401-408
• 36 Lorenz D, Schwieger D, Moises H, Deuschl G. Quality of life and personality in essential tremor patients.  Mov Disord. 2006;  21 (8) 1114-1118
• 37 Nguyen H V, Ngian V, Cordato D, Shen Q, Chan D K. Quality of life in a random sample of community dwelling older patients with essential tremor.  Acta Neurol Scand. 2007;  116 (5) 289-292
• 38 Lyons K E, Pahwa R. Pharmacotherapy of essential tremor : an overview of existing and upcoming agents.  CNS Drugs. 2008;  22 (12) 1037-1045
• 39 Zesiewicz T A, Elble R, Louis E D Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2005;  64 (12) 2008-2020
• 40 Elble R J. Tremor: clinical features, pathophysiology, and treatment.  Neurol Clin. 2009;  27 (3) 679-695, v–vi v-vi
• 41 Simpson D M, Blitzer A, Brashear A Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 2008;  70 (19) 1699-1706
• 42 Bain P G, Findley L J, Thompson P D et al.. A study of hereditary essential tremor.  Brain. 1994;  117 (Pt 4) 805-824
• 43 Rehncrona S, Johnels B, Widner H, Törnqvist A L, Hariz M, Sydow O. Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments.  Mov Disord. 2003;  18 (2) 163-170
• 44 Herzog J, Hamel W, Wenzelburger R et al.. Kinematic analysis of thalamic versus subthalamic neurostimulation in postural and intention tremor.  Brain. 2007;  130 (Pt 6) 1608-1625
• 45 Gourie-Devi M, Ramu M G, Venkataram B S. Treatment of Parkinson's disease in ‘Ayurveda’ (ancient Indian system of medicine): discussion paper.  J R Soc Med. 1991;  84 (8) 491-492
• 46 Elizan T S, Sroka H, Maker H, Smith H, Yahr M D. Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients.  J Neural Transm. 1986;  65 (3-4) 285-302
• 47 Brooks D J, Playford E D, Ibanez V et al.. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study.  Neurology. 1992;  42 (8) 1554-1560
• 48 Carr J. Tremor in Parkinson's disease.  Parkinsonism Relat Disord. 2002;  8 (4) 223-234
• 49 Dickson D W, Braak H, Duda J E et al.. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.  Lancet Neurol. 2009;  8 (12) 1150-1157
• 50 Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal ‘hyperdirect’ pathway.  Neurosci Res. 2002;  43 (2) 111-117
• 51 Nambu A. A new approach to understand the pathophysiology of Parkinson's disease.  J Neurol. 2005;  252 (Suppl 4) IV1-IV4
• 52 Lévesque M, Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies.  Proc Natl Acad Sci U S A. 2005;  102 (33) 11888-11893
• 53 Nadjar A, Brotchie J M, Guigoni C et al.. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia.  J Neurosci. 2006;  26 (34) 8653-8661
• 54 Zaidel A, Arkadir D, Israel Z, Bergman H. Akineto-rigid vs. tremor syndromes in Parkinsonism.  Curr Opin Neurol. 2009;  22 (4) 387-393
• 55 Vingerhoets F J, Schulzer M, Calne D B, Snow B J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?.  Ann Neurol. 1997;  41 (1) 58-64
• 56 Weinberger M, Hutchison W D, Dostrovsky J O. Pathological subthalamic nucleus oscillations in PD: can they be the cause of bradykinesia and akinesia?.  Exp Neurol. 2009;  219 (1) 58-61
• 57 Stochl J, Boomsma A, Ruzicka E, Brozova H, Blahus P. On the structure of motor symptoms of Parkinson's disease.  Mov Disord. 2008;  23 (9) 1307-1312
• 58 Kühn A A, Tsui A, Aziz T et al.. Pathological synchronisation in the subthalamic nucleus of patients with Parkinson's disease relates to both bradykinesia and rigidity.  Exp Neurol. 2009;  215 (2) 380-387
• 59 Penn R D, Kroin J S, Reinkensmeyer A, Corcos D M. Injection of GABA-agonist into globus pallidus in patient with Parkinson's disease.  Lancet. 1998;  351 (9099) 340-341
• 60 Langston J W. The Parkinson's complex: parkinsonism is just the tip of the iceberg.  Ann Neurol. 2006;  59 (4) 591-596
• 61 Pogarell O, Gasser T, van Hilten J J et al.. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.  J Neurol Neurosurg Psychiatry. 2002;  72 (6) 713-720
• 62 Schrag A, Keens J, Warner J. Ropinirole Study Group . Ropinirole for the treatment of tremor in early Parkinson's disease.  Eur J Neurol. 2002;  9 (3) 253-257
• 63 Navan P, Findley L J, Jeffs J A, Pearce R K, Bain P G. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.  Mov Disord. 2003;  18 (2) 176-180
• 64 Navan P, Findley L J, Jeffs J A, Pearce R K, Bain P G. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.  Mov Disord. 2003;  18 (11) 1324-1331
• 65 Möller J C, Eggert K M, Unger M, Odin P, Chaudhuri K R, Oertel W H. Clinical risk-benefit assessment of dopamine agonists.  Eur J Neurol. 2008;  15 (Suppl 2) 15-23
• 66 van Hilten J J, Ramaker C C, Stowe R, Ives N J. Bromocriptine versus levodopa in early Parkinson's disease.  Cochrane Database Syst Rev. 2007;  (4) CD002258
• 67 Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees A J. Parkinson's Disease Research Group of the United Kingdom . Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.  Neurology. 2008;  71 (7) 474-480
• 68 Crosby N J, Deane K H, Clarke C E. Beta-blocker therapy for tremor in Parkinson's disease.  Cochrane Database Syst Rev. 2003;  (1) CD003361
• 69 Segrell N D, Granérus A-K, Holmberg B et al.. [Swedish Guidelines for the Diagnosis and Treatment of Parkinson's Disease]. Revised version #3 2009 Available at: http://www.swemodis.se/images/Dokument/riktlinjer2009.pdf Accessed January 10, 2011
• 70 Krack P, Pollak P, Limousin P, Benazzouz A, Benabid A L. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease.  Lancet. 1997;  350 (9092) 1675
• 71 Follett K A, Weaver F M, Stern M CSP 468 Study Group et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.  N Engl J Med. 2010;  362 (22) 2077-2091
• 72 Köller H, Kieseier B C, Jander S, Hartung H P. Chronic inflammatory demyelinating polyneuropathy.  N Engl J Med. 2005;  352 (13) 1343-1356
• 73 Ropper A H, Gorson K C. Neuropathies associated with paraproteinemia.  N Engl J Med. 1998;  338 (22) 1601-1607
• 74 Netravathi M, Pal P K, Ravishankar S, Indira Devi B. Electrophysiological evaluation of tremors secondary to space occupying lesions and trauma: correlation with nature and sites of lesions.  Parkinsonism Relat Disord. 2010;  16 (1) 36-41
• 75 Gajos A, Bogucki A, Schinwelski M et al.. The clinical and neuroimaging studies in Holmes' tremor.  Acta Neurol Scand. 2010;  122 (5) 360-366
• 76 Breakefield X O, Blood A J, Li Y, Hallett M, Hanson P I, Standaert D G. The pathophysiological basis of dystonias.  Nat Rev Neurosci. 2008;  9 (3) 222-234
• 77 Ostrem J L, Starr P A. Treatment of dystonia with deep brain stimulation.  Neurotherapeutics. 2008;  5 (2) 320-330
• 78 Bain P G, Findley L J, Britton T C et al.. Primary writing tremor.  Brain. 1995;  118 (Pt 6) 1461-1472
• 79 Bhidayasiri R. Differential diagnosis of common tremor syndromes.  Postgrad Med J. 2005;  81 (962) 756-762
• 80 Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor.  J Neurol Sci. 2007;  263 (1-2) 94-99
• 81 Deuschl G, Köster B, Lücking C H, Scheidt C. Diagnostic and pathophysiological aspects of psychogenic tremors.  Mov Disord. 1998;  13 (2) 294-302
• 82 Freund H J, Barnikol U B, Nolte D et al.. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit.  Mov Disord. 2007;  22 (5) 732-735
• 83 Brown P. New clinical sign for orthostatic tremor.  Lancet. 1995;  346 (8970) 306-307
• 84 Britton T C, Thompson P D, van der Kamp W et al.. Primary orthostatic tremor: further observations in six cases.  J Neurol. 1992;  239 (4) 209-217
• 85 Raethjen J, Deuschl G. [Tremor].  Ther Umsch. 2007;  64 (1) 35-40
• 86 Sharma P, Eesa M, Poppe A Y, Goyal M. Teaching NeuroImage: posttraumatic palatal tremor.  Neurology. 2008;  71 (13) e30
• 87 Raethjen J, Kopper F, Govindan R B, Volkmann J, Deuschl G. Two different pathogenetic mechanisms in psychogenic tremor.  Neurology. 2004;  63 (5) 812-815